Lunai Bioworks Inc.
Lunai Bioworks is a biotechnology company based in Los Angeles, California, focused on precision medicine, biomarker discovery and therapeutic development. It operates principally through Renovaro Biosciences and BioSymetrics and has no products on the market. Renovaro Biosciences has cell and gene therapy programs focused on cancer and infectious diseases. BioSymetrics combines artificial intelligence with experimental biology, using technologies including Contingent AI and the Phenograph knowledge graph. It collaborates with pharmaceutical companies, healthcare providers and academic institutions on analytical tools and research programs. Lunai also has a commercial collaboration involving AI-powered chemical threat assessment and receives grant funding for therapeutic discovery programs. Its Lunai Bioworks IP subsidiary holds intellectual property for the N2B intranasal drug delivery platform, with rights limited to biodefense medical countermeasures and Alzheimer’s disease.
No SEC Form 4 filings for $LNAI in the last 30 days.
See all $LNAI insider activity →Lunai Bioworks CFO Nathen Fuentes and Director Douglas W. Calder resigned on October 22, 2026. Fuentes cited no disagreement over accounting principles, while Calder stated no disagreement with company operations. No successors were named, and the board now has three directors.
Lunai Bioworks (LNBI) will delist from Nasdaq on Nov. 12, 2026, due to financial conditions. The company will not seek an alternative trading market and may suspend SEC reporting. The board approved the withdrawal on Oct. 22, 2026, citing high listing and reporting costs.
Lunai Bioworks Inc. reported FY 2026 revenue of $52K, a net loss of $3.56M, and EPS of $(1.06), improving from FY 2025. The company shifted focus to AI-driven precision medicine, reduced costs, and acquired IP to accelerate R&D. Programs remain preclinical, and additional financing is being pursued.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning LNAI (Lunai Bioworks Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 6 bearish.
Recent LNAI coverage spans technology, financial news and corporate actions.
The sudden leadership departures create uncertainty about financial oversight and governance.
Lunai Bioworks (LNBI) will delist from Nasdaq on Nov. 12, 2026, due to financial conditions. The company will not seek an alternative trading market and may suspend SEC reporting. The board approved the withdrawal on Oct. 22, 2026, citing high listing and reporting costs.
Results show continued near-zero revenue but a large improvement in losses, alongside a strategic pivot to AI-driven precision medicine.
The halt request signals potential regulatory or market‑structure issues, likely increasing sell pressure.
Potential suspension could halt trading and depress share price.
AlphAI scores every news story that mentions LNAI with an AI model for sentiment and relevance, and aggregates insider trades from Lunai Bioworks Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lunai Bioworks CFO Nathen Fuentes and Director Douglas W. Calder resigned on October 22, 2026. Fuentes cited no disagreement over accounting principles, while Calder stated no disagreement with company operations. No successors were named, and the board now has three directors.
1 min readLunai Bioworks (LNBI) will delist from Nasdaq on Nov. 12, 2026, due to financial conditions. The company will not seek an alternative trading market and may suspend SEC reporting. The board approved the withdrawal on Oct. 22, 2026, citing high listing and reporting costs.
2 min readLunai Bioworks Inc. reported FY 2026 revenue of $52K, a net loss of $3.56M, and EPS of $(1.06), improving from FY 2025. The company shifted focus to AI-driven precision medicine, reduced costs, and acquired IP to accelerate R&D. Programs remain preclinical, and additional financing is being pursued.
1 min readLunai Bioworks (LNAI) asked Nasdaq to halt trading due to alleged irregular short-selling. The company cited substantial short selling and failures to deliver, according to court-ordered discovery records. The request follows pending litigation against Seven Points Capital. Nasdaq has not yet decided on the request, and trading continues.
1 min readLunai Bioworks Inc. (LNAI) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 9, 2026, Lunai Bioworks, Inc. (the “Company”) submitted a formal request to The Nasdaq Stock Market LLC (“Nasdaq”) asking Nasdaq to immediately suspend trading in the Company’s common stock to protect investors while Nasdaq, FINRA and other app
1 min readLunai Bioworks (NASDAQ: LNAI) has entered an exclusive agreement with Tanaist to enhance its Parkinson's disease research platform. The collaboration aims to validate AI-identified patient subtypes with human cellular biology, potentially advancing biomarker and therapeutic target development. Lunai will have exclusive rights to Tanaist's technology for Parkinson's programs based on its patient phenoclusters.
1 min readLunai Bioworks (Nasdaq: LNAI) announced a study by its subsidiary BioSymetrics, demonstrating AI-based chemical-risk screening for AI-generated compounds. The study achieved 5.1-fold enrichment in predicting acetylcholinesterase (AChE) inhibition, a relevant benchmark for chemical-hazard triage. The company aims to complement existing AI safeguards with structure-based screening, addressing dual-use risks in AI-enabled science. Lunai seeks collaborations with AI developers like OpenAI and Anthro
2 min readLunai Bioworks (LNAI) filed a Second Amended Complaint in Delaware court, adding six broker-dealers and two principals as defendants. The suit alleges securities fraud and market manipulation under Rule 10b-5. The company is an AI-driven precision medicine platform focused on therapeutics and biodefense. The outcome of the lawsuit is uncertain, and the allegations have not been proven.
2 min readLunai Bioworks (Nasdaq: LNAI) said it signed a definitive Master Collaboration Agreement with BrainStorm Therapeutics to develop precision neuroscience programs for Parkinson’s disease. Lunai’s BioSymetrics subsidiary published a white paper using the PPMI dataset to identify Parkinson’s subtypes and proteomic signatures. The companies target an initial data readout in 1H 2027.
4 min readLunai Bioworks (Nasdaq: LNAI) said it filed a First Amended Complaint naming 10 defendants, including three FINRA broker dealers, in a naked short selling fraud suit. The company alleges 29.6 million failed-to-deliver shares and that failures to deliver exceeded 80% of shares outstanding from Nov 2025 to May 2026, citing a March 17 trade volume 15.3 times shares outstanding. It seeks treble damages under RICO and other relief.
4 min read
